Adjuvant and neoadjuvant therapies of pancreatic cancer |
| |
Authors: | Jules Harris and Howard Bruckner |
| |
Affiliation: | (1) Department of Internal Medicine, Rush Medical College, 60612 Chicago, IL;(2) Department of Medicine, St. Luke’s Roosevelt Hospital Center, 10019 New York, NY;(3) Professional Bldg., Section of Medical Oncology, Rush-Presbyterian-St. Luke’s Medical Center, 1725 W. Harrison Street, 60612 Chicago, IL |
| |
Abstract: | Summary The survival of patients diagnosed with pancreatic cancer is dismal. Few patients on initial presentation are suitable for
surgical resection. This has prompted clinical studies with chemotherapy and/or radiotherapy designed either to increase the
number of patients eligible for surgery (neoadjuvant therapy) or to prolong the survival of patients who had undergone surgery
(adjuvant therapy). None of these studies may at this time be considered definitive. Wherever possible, patients felt eligible
for neoadjuvant or adjuvant therapy should be entered on clinical trials. Where this is not possible, clinicians should exercise
their best judgment in offering this type of treatment to pancreatic cancer patients under their care. |
| |
Keywords: | Pancreatic cancer adjuvant therapy neoadjuvant therapy chemotherapy/radiotherapy of pancreatic cancer |
本文献已被 SpringerLink 等数据库收录! |
|